AZV – European Partnerships: PerMed / ERDERA / OH AMR
European Partnership PerMed (Personalised Medicine)
AZV has published preliminary information regarding the upcoming PerMed call, expected to be launched at the beginning of October 2025: "Test and Demonstration of Multimodal Data Approaches for Personalised Medicine (MultiPMData2026)", with a deadline for pre-proposals on 12 January 2026.
Aim of the call:
- To connect businesses with clinical stakeholders, including healthcare providers, patients, and researchers, in order to test innovative solutions under controlled real-world conditions. These solutions should address specific and clearly defined needs in the care of patients with multiple chronic conditions requiring long-term and coordinated care (i.e., multimorbidity).
- To fund innovative projects in the field of human health, focused on the use of diverse (multimodal) data within personalised medicine approaches. The goal is to improve and individualise patient care management for those suffering from two or more chronic illnesses requiring continuous healthcare (i.e., multimorbidity).
In connection with the EP PerMed partnership, we would like to remind you of the open Networking Call with a deadline of 29 September 2025.While the main PI and one of the partners must already be involved in a current or past EP PerMed call, the third partner only needs to have participated in a (inter)national project in the field of personalised medicine.This Networking Call allows funding of only one activity per application, up to EUR 30,000 (e.g., workshop, conference, in-person or hybrid meeting)
European Partnership ERDERA (Rare Diseases)
Call under the Networking Support Scheme – a continuous call with evaluations conducted every 6 months.
Only one activity per applicant can be funded under this scheme, with a maximum amount of EUR 30,000 (e.g., workshop, conference, in-person or hybrid meeting).
Each applying consortium must include 3–10 eligible participants from at least 3 different countries.
European Partnership OH AMR (Antimicrobial Resistance)
The first call is expected to be launched on 18 November 2025, focusing on the provision of innovative and cost-effective treatment option.